NeoGenomics, Inc. (FRA:NG9)

Market Cap	1.09B -37.2%
Revenue (ttm)	619.47M +10.1%
Net Income	-92.00M
EPS	-0.72
Shares Out	n/a
PE Ratio	n/a
Forward PE	63.53
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	8.45
Previous Close	8.60
Day's Range	8.45 - 8.45
52-Week Range	4.20 - 12.10
Beta	n/a
RSI	29.40
Earnings Date	Feb 17, 2026

About NeoGenomics

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and ge...

• Industry: Medical Laboratories
• Founded: 2001
• Employees: 2,500
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: NG9

Financial Performance

In 2025, NeoGenomics's revenue was $727.33 million, an increase of 10.11% compared to the previous year's $660.57 million. Losses were -$108.03 million, 37.2% more than in 2024.

Financial numbers in USD